StalkMedium
Stage 2 advance remains intact with a breakout above resistance, but extreme overextension and overbought readings warn of a potential reversal. We defer entries and stalk for a pullback into the 9/21 EMA support zone to confirm acceptance before buying.
- ↑86% of AUM outperformed benchmarks over past year, highlighting CNS’s performance edge.
- ↑Q1 revenue rose to $144.3M with $497M net inflows, reflecting strong investor demand.
- ↓Negative growth factors and downward analyst revisions indicate revenue expansion challenges.
Full analysis →